Covidien wins injunction against J&J; MedAvail nabs $30M;

Medical Device News

@FierceMedDev: Medical device venture deals pull in more money per deal. More | Follow @FierceMedDev

@VarunSaxena2: ICYMI: Invitae raises $120M to offer cheap, easy genetic analysis. Story | Follow @VarunSaxena2

@EmilyWFierce: Stryker scores with Q3 earnings, beating the Street's expectations and posting $2.39B in revenue. Article | Follow @EmilyWFierce

@MichaelGFierce: Stealthy, DNA-based 'nano-cocoons' deliver #cancer-killing payloads. News | Follow @MichaelGFierce

> MedAvail Technologies got a $30 million Series C round to commercialize its prescription drug-dispensing kiosks for consumers that it expects to locate in hospitals, clinics, pharmacies and other locations. The financing was led by Pura Vida Investments, which was joined by Deerfield Management and Adage Capital; all of them are new investors. Existing investors Redmile Group, Walgreens and Alliance Boots also participated. Release

> The Wall Street Journal talks to Dr. Wen Dombrowski about why health technology providers should target the sick, rather than the wealthy well. Story

> The U.S. District Court for the District of Connecticut has granted a preliminary injunction against Ethicon Endo-Surgery, a Johnson & Johnson ($JNJ) company, in a lawsuit filed by Covidien ($COV) in June. It prevents from manufacturing, marketing or selling the ultrasonic surgical product Harmonic ACE+7, which Covidien alleges infringes on three patents. The same court previously awarded damages against Ethicon of more than $175 million, which is now under appeal. Story

Biotech News

@FierceBiotech: Astellas backs out of a $760M Alzheimer's deal with CoMentis. Item | Follow @FierceBiotech

@JohnCFierce: This low-T field is definitely starting to look like the slum area of R&D. | Follow @JohnCFierce

@DamianFierce: Early look at Adaptimmune's cancer immunotherapy data: 1 complete response and 3 partials among 5 patients. Story | Follow @DamianFierce

@EmilyMFierce: The long and ugly tradition of treating Africa as a dirty, diseased place. More | Follow @EmilyMFierce

> Amgen sues to block Sanofi and Regeneron at the PCSK9 goal line. Article

> Repros plummets as the FDA deals a blow to its low-T hopes. Story

> Adaptimmune's novel cancer treatment posts promising early results. More

Pharma News

@FiercePharma: Tops in FierceVaccines Thurs: NewLink Ebola vaccine trial begins in U.S. while Glaxo takes its jab to Mali. Story | Follow @FiercePharma

@EricPFierce: I suspect Laura Schumacher spent late nights as AbbVie board decided whether to walk away from Shire deal. Report | Follow @EricPFierce

@CarlyHFierce: ICYMI: This week's issue of FierceVaccines. Subscribe here to get it weekly. Subscribe | Follow @CarlyHFierce

> Lilly will close Puerto Rico plant affecting 100 workers. Article

> FDA says Pfizer's Chantix must continue to wear a 'black box' label. Story

> AbbVie's $1.635B breakup fee to Shire, if paid, will run third highest ever. Item

Suggested Articles

Johnson & Johnson Vision announced that the worldwide president of its surgical business, Tom Frinzi, plans to retire at the end of this year.

Philips looked back on 15 years of data from one of its telehealth-equipped intensive care units, where centralizing operations reduced mortality.

Sanofi will look to pull back from its three-year-old relationship with Verily and their virtual diabetes clinic, Onduo.